Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Completed

• Conditions: Hyperlipidemias; Peripheral Vascular Diseases; Diabetes Mellitus; Atherosclerosis; Coronary Heart Disease; Carotid Stenosis

• Registration Number: NCT00536965
• Lead Sponsor: AstraZeneca

Brief Summary

A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is \<100mg/dl for patients with high risk and \<70mg/dl for patients at very high risk) are screened (office-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-07
• Study First Submitted: 2007-09-27
• Study First Submitted QC: 2007-09-27
• Study First Posted: 2007-09-28
• Primary Completion: 2007-12
• Study Completion: 2007-12
• Status Verified: 2014-10
• Last Update Submitted: 2014-10-29
• Last Update Posted: 2014-10-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 951

Inclusion Criteria

• Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy

Read More

Exclusion Criteria

• Patients who do not receive cholesterol-lowering therapy

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Lipid profile	At screening and 8-5 weeks after screening
HbA1c profile	At screening and 8-5 weeks after screening

Trial Locations

Locations (1)

Research Site; 🇦🇹 Vienna, Austria